Yeah, I took a small position back in April after stumbled across them when they were sub 9cents. Can feel for long term holders as the continued dilution has not been great.
But they now have very interesting drug development pathways and amazing that it has taken a major investor like Karst Peak Capital to pique the market interest. Still a very low market cap as revenues are not growing as strongly as hoped due to covid. Very high cash burn with keeping manufacturing in house in Oz, however the steps taken to licence off the Russian and Australian markets will help to significantly reduce costs for this fin year.
Very excited about the fibrosis and skin scaring markets.
